Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation

ABSTRACT

New-onset post-cardiac surgery atrial fibrillation (PCSAF) is a frequent complication with estimated incidence of 17% to 64%, depending on type of surgery. It is associated with higher mortality, morbidity, and predisposition to stroke and systemic embolism postoperatively. Standard care involves rate or rhythm control, in addition to antithrombotic therapy in those with history of stroke, transient ischemic attack, or high risk of systemic thromboembolism. However, risk of bleeding is not negligible, and treating physicians should weigh the risks and benefits before committing to postoperative anticoagulation therapy. More investigations are warranted to explore antithrombotic therapy benefit, particularly postoperative anticoagulation, considering the potentially self-limited nature of the arrhythmia and high risk of postoperative bleeding.

KEY POINTS

Anticoagulation should be weighed against potential risk of postoperative bleeding for patients with new-onset PCSAF as it is potentially transient and self-limited.

Avoid anticoagulation therapy for transient atrial fibrillation < 48 hours.

Anticoagulation is usually recommended for 4 to 6 weeks after atrial fibrillation conversion owing to enhanced risk of thrombosis resulting from persistent weak atrial contraction.

THERE IS NO EXACT CONSENSUS regarding the definition of new-onset post-cardiac surgery atrial fibrillation (PCSAF), and thus criteria for diagnosis are set by individual institutions. Our definition of new-onset atrial fibrillation is any duration detected on 12-lead electrocardiography or on a telemetry strip, developed in patients after cardiac surgery without previous diagnosis of atrial fibrillation, regardless of need for treatment. Cardiac surgery is defined as coronary artery bypass grafting (CABG), valve surgery, or a combination of both procedures. Studies have determined the postoperative timing of new-onset atrial fibrillation to range from the first 10 days postoperatively1 to the first 30 days after surgery,2 as well as during hospitalization only.3

The purpose of this review is to evaluate the studies, professional society recommendations, and expert thoughts on knowledge gaps relevant to anticoagulation therapy of new-onset PCSAF.

EPIDEMIOLOGY

With little change over the past 20 years, new-onset PCSAF is estimated to occur in the postoperative period in 17% to 40% after isolated CABG surgery,4–7 38% to 64% after heart valve surgery,3,4,7 and as high as 62% after combined procedures.1,3,4,6

New-onset PCSAF tends to develop within the first few days postoperatively,1,5 with the highest incidence seen on postoperative day 2, while most recurrence happens by postop-
Few patients develop new-onset atrial fibrillation in the very early postoperative period or 4 days or more after surgery. In patients who have no prior history of atrial fibrillation, new-onset PCSAF is usually transient in nature, as up to 80% revert to sinus rhythm within 24 hours, and the majority of patients (90%) are in sinus rhythm 6 to 8 weeks after discharge.

**THE IMPACT OF NEW-ONSET POST-CARDIAC SURGERY ATRIAL FIBRILLATION**

Potential adverse events following new-onset PCSAF include thromboembolic complications, worsening of comorbid medical conditions, and increased mortality. Of interest, is the potentially increased rate of postoperative thromboembolic complications including stroke leading to the potential role of anticoagulation therapy in their prevention.

**Short-term complications**

In multiple series, new-onset PCSAF had been associated with increased in-hospital postoperative stroke and increased mortality. These findings were similar in both on-pump (with cardiopulmonary bypass) and off-pump (without cardiopulmonary bypass) CABG surgery, and with and without valve surgery.

There is considerable debate as to whether new onset atrial fibrillation has a high risk of recurrence after discharge.

On the other hand, other single-center studies failed to find an association between new-onset PCSAF and increased risk of in-hospital stroke. In one study, more than half of strokes occurred postoperatively rather than intraoperatively, and new-onset PCSAF was not associated with increased risk of stroke. However, older age and variables indicative of arteriosclerotic burden were risk factors for both intraoperative and postoperative stroke.

**Long-term complications**

In most reports, new-onset PCSAF has been associated with worse long-term survival and increased thromboembolic complications. For instance, in the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization trial of patients with left main coronary artery disease who underwent revascularization with either CABG or percutaneous coronary intervention, new-onset atrial fibrillation was an independent stroke predictor at three years in CABG patients.

In another cohort study of patients who had undergone CABG surgery, risk of thromboembolism was lower in the PCSAF group than in the group with atrial fibrillation that was not valvular. Anticoagulation was associated with a lower risk of thromboembolic events in both groups, and thromboembolism was not significantly higher in patients with new-onset PCSAF compared with those who did not develop new-onset atrial fibrillation after surgery.

**Risk of recurrence**

There is considerable debate as to whether atrial fibrillation developing after cardiac surgery has a high risk of recurrence and thus whether extended anticoagulation therapy to prevent thromboembolism can be beneficial. A recent meta-analysis analyzed 8 studies with a total of 1,157 participants monitored for new-onset PCSAF recurrence after discharge, all of whom were discharged in sinus rhythm and subsequently monitored by both noninvasive and invasive devices. Monitoring identified recurrence in 28.3 per 100 persons screened in the first 2 to 4 weeks after discharge using noninvasive techniques. Implanted devices identified recurrence in 61% to 100% of cases, suggesting that in-hospital PCSAF episodes are not transient. Most recurrences were asymptomatic and thus likely to be overlooked without the use of monitoring after hospital discharge.

**ANTICOAGULATION THERAPY FOR POST-CARDIAC SURGERY ATRIAL FIBRILLATION**

**Evidence behind anticoagulation and benefits**

In medical patients with chronic or recurrent atrial fibrillation, the cause-and-effect relationship between atrial arrhythmias and thromboembolic events has been thoroughly examined; however, this relationship has not been evaluated in the post-cardiac surgery setting. Current recommendations from the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) 2014 and 2019 updated guidelines is to use warfarin (to target an international normalized ratio [INR] 2–3) and novel oral anticoagulants in patients with history of stroke, transient ischemic attack, or CHA2DS2-VASc score ≥ 2, defined as patients with congestive heart failure, hypertension, age ≥ 75, diabetes, stroke, vascular disease, age 65 to 74, and female.
The question remains whether these guidelines are applicable to new-onset PCSAF in the postoperative period, taking into account the following facts:

- Risk of bleeding may be significant in the postoperative period
- CHA2DS2-VASc is a risk stratification tool that assesses annual stroke risk, however, has not been studied as an instrument for predicting postoperative stroke and embolic phenomena
- In current literature, high-quality evidence of early postoperative antithrombotic therapy benefits in thromboembolic complications is lacking.

Kollar and colleagues described a retrospective study regarding benefits of anticoagulation in the postoperative period of 2,960 patients after CABG with 32 patients having had a postoperative stroke. The study was unique in that it examined the temporal relationship between postoperative atrial fibrillation and stroke. Seventeen of these patients continued to maintain sinus rhythm during their hospitalization. Of the remaining 15 patients, 9 had neurologic deficits before the first episode of atrial fibrillation. Of the 6 patients with atrial fibrillation preceding neurologic events, three strokes occurred within 1 week after spontaneous conversion to normal sinus rhythm. One patient with preoperative as well as intraoperative atrial fibrillation underwent emergency CABG surgery and woke up with a stroke. In the remaining two cases, the atrial fibrillation or atrial flutter episodes lasted less than 6 hours each before the onset of neurologic events. Authors concluded that aggressive anticoagulation as suggested in current guidelines could not have decreased the already low incidence of postoperative stroke. The study, however, was underpowered making it difficult to draw a conclusion that is generalizable to a large cohort. An adequately powered prospective registry evaluating the benefits of anticoagulation in the early postoperative period is warranted.

**Risk of postoperative bleeding with anticoagulation**

The questionable rationale of early anticoagulation in reducing postoperative stroke is impacted by the risk of associated bleeding in the postoperative period. For instance, there was a significant increase in large pericardial effusions and tamponade occurring one week or more after surgery in a study of patients treated with warfarin compared with the antiplatelet control group, especially when excessively anticoagulated (INR above therapeutic target).

Bleeding other than at the surgical site might be relevant when determining use of anticoagulants, particularly with gastrointestinal hemorrhage. In a single-center, retrospective analysis of 9,017 patients undergoing cardiac surgery, the incidence of endoscopy-requiring gastrointestinal hemorrhage was 1.01%, and 30-day mortality was higher in patients who bled compared with patients who did not. The study was limited in that only bleeding events requiring intervention were included.

HAS-BLED is a risk score, defined as hypertension, abnormal renal or liver function, stroke, bleeding history or predisposition, labile INR, elderly (age > 65), and drugs or alcohol concomitantly, that is often used to determine use of anticoagulation therapy by evaluating risks and benefits in the general population with atrial fibrillation that is not valvular. However, validity in patients after surgery has not been evaluated. Thus, a high-quality risk stratification tool to identify bleeding in surgical patients would be of great clinical value.

**Recommendations of professional societies**

The AHA/ACC/HRS guidelines recommend considering using anticoagulation medication for patients who develop new-onset postoperative atrial fibrillation as administered for nonsurgical patients. The American College of Chest Physicians suggests weighing the AHA/ACC/HRS recommendations in the context of the usually transient and self-limited duration of new-onset PCSAF against the potential risk of bleeding and recommends starting anticoagulation therapy if atrial fibrillation persists 48 hours and beyond. They further state that therapy should be continued for 30 days after the return to normal sinus rhythm because of persistent atrial contraction impairment and possible enhanced risk of thrombosis following cardioversion to sinus rhythm. The Canadian Cardiovascular Society Atrial Fibrillation Guidelines recommend continuing anticoagulation for new-onset PCSAF for a minimum of 6 weeks, although the American College of Chest Physicians and AHA/ACC/HRS did not provide details regarding timing of initiation of antithrombotic therapy. A report from the European Association for Cardio-Thoracic Surgery does not recommend immediate full antithrombotic therapy when new-onset atrial fibrillation develops within 48 hours of cardiac surgery, due to increased risk of cardiac tamponade. Table 1 provides a summary of these recommendations, and Figure 1 shows our proposed algorithm for management of new-onset PCSAF.
Selection of drugs

The American College of Chest Physicians and AHA/ACC/HRS recommend anticoagulation therapy with warfarin, with or without heparin for atrial fibrillation. Novel oral anticoagulants have been included in the 2014 and 2019 updated AHA/ACC/HRS guidelines. More recently, the 2019 report added idarucizumab and andexanet alfa for the reversal of direct thrombin and activated factor Xa inhibitors, respectively. In one retrospective review, patients were administered anticoagulation with either warfarin or novel oral anticoagulants for new-onset PCSAF in the postoperative period; both drug classes were found to be safe and effective methods of anticoagulation with no significant difference between outcomes of strokes.

TABLE 1

Recommendations of professional societies

| Professional society | Recommendations | Class of recommendations/level of evidence |
|----------------------|----------------|-------------------------------------------|
| AHA/ACC/HRS<sup>22</sup>,<sup>23</sup> | It is reasonable to administer antithrombotic medication in patients who develop postoperative AF, as recommended for nonsurgical patients | Class IIA: (benefit greater than risk, additional studies with focused objectives needed, it is reasonable to administer treatment Level of Evidence: B (limited population evaluated, data derived from a single randomized trial or nonrandomized studies) |
| ACCP<sup>28</sup> | A: Postoperative use of heparin in high-risk patient | Strength of recommendation: C Evidence grade: Low Net benefit: Intermediate |
| | B: Postoperative use of warfarin in patient with chronic AF and in whom it is thought likely that AF will continue | Strength of recommendation: A Evidence grade: Good Net benefit: Substantial |
| | C: Duration of anticoagulation therapy is 30 days after return of sinus rhythm | Strength of recommendation: C Evidence grade: Low Net benefit: Intermediate |
| CCS<sup>29</sup> | Anticoagulation is recommended for patients with prolonged (≥ 72 hours) AF Once initiated, anticoagulation is usually continued for 6 weeks | Low-quality evidence |
| EACTS<sup>30</sup> | A: After cardiac surgery, patients with AF should be anticoagulated while in AF, and full anticoagulation should be started within 48 hours of AF onset due to doubling of risk of stroke This can be achieved with warfarin (INR 2–3), intravenous heparin, or full-dose low-molecular-weight heparin | Grade A recommendation based on level 1A studies |
| | B: Immediate full anticoagulation in patients going into AF within 48 hours of their operation is not supported due to increased risk of cardiac tamponade | Grade C recommendation based on an individual level 2B study |
| | C: There is insufficient evidence to recommend whether patients who suffer from an episode of AF after cardiac surgery but who return to sinus rhythm will benefit from further 4 to 6 weeks of anticoagulation | Grade E recommendation based on expert consensus |

ACC = American College of Cardiology; ACCP = American College of Chest Physicians; AF = atrial fibrillation; AHA = American Heart Association; CCS = Canadian Cardiovascular Society; EACTS = European Association for Cardio-Thoracic Surgery; HRS = Heart Rhythm Society; INR = international normalized ratio
postoperative hemorrhage, and hospital length of stay.\textsuperscript{31} The study was small and limited to the hospital postoperative period. Two other small pilot studies compared edoxaban\textsuperscript{32} and apixaban\textsuperscript{33} to warfarin for new-onset PCSAF and demonstrated safety and efficacy while suggesting larger scale clinical trials for further evaluation. A randomized clinical trial comparing rivaroxaban and warfarin for new-onset PCSAF is currently under way.\textsuperscript{34}

Monitoring of therapy and discontinuation of anticoagulants

There is a lack of evidence regarding monitoring following discharge for new-onset PCSAF patients who revert to sinus rhythm before discharge. Consequently, some hospitals have developed institutional policies regarding follow up and monitoring of patients that relies on expert opinion. For instance, a feasibility cross-sectional study with a unique idea of self-monitoring assessed 42 patients who had undergone cardiac surgery (CABG, valve surgery, or combination) for new-onset PCSAF recurrence using smartphone handheld electrocardiogram devices.\textsuperscript{35} Study participants were instructed to record rhythm for 30 seconds, 4 times daily, for 4 weeks after discharge. Owing to the feasibility of the study, there was no control group, randomization, or blinding. Self-monitoring identified 24% with atrial fibrillation recurrence within 17 days of hospital discharge. Surprisingly, patients with atrial fibrillation recurrence were younger and had a lower CHA\textsubscript{2}DS\textsubscript{2}-VASc score than those without atrial fibrillation recurrence. Results should be interpreted with caution.

**Figure 1.** Proposed algorithm for management of new-onset atrial fibrillation following cardiac surgery.

AF = atrial fibrillation; CHA\textsubscript{2}DS\textsubscript{2}-VASc = congestive heart failure, hypertension, age ≥ 75, diabetes, stroke, vascular disease, age 65 to 74, and female; PCSAF = post-cardiac surgery atrial fibrillation
tion owing to the small sample size, infrequent self-monitoring, and study duration. Additional atrial fibrillation episodes may have been detected with a larger sample size and longer daily monitoring.

### CONCLUSIONS

Adequately powered, large prospective studies are needed to investigate the relationship between transient atrial fibrillation and subsequent thromboembolic events in the postoperative period. Assessment of risk of hemorrhage in the immediate (first 48 hours) and later (≥ 48 hours to 7 days) postoperative period must be validated for cardiac surgery patients in large scale settings and may help to predict bleeding risk and allow for evaluation of postoperative anticoagulants. It is important to identify risk assessment models other than CHA2DS2-VASc score while considering operative technique to help identify patients at high risk in the setting of cardiac surgery. Finally, multicenter randomized trials investigating the benefits and risks of anticoagulation therapy indicated for transient atrial fibrillation early after cardiac surgery are warranted.

### DISCLOSURES

The authors report no relevant financial relationships, which, in the context of their contributions, could be perceived as a potential conflict of interest.

14. Butt JH, Xian Y, Peterson ED, et al. Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol 2018; 3(5):417–424. doi:10.1001/jamacardio.2018.0005

15. Kosmidou I, Chen S, Kappetein AP, et al. New-onset atrial fibrillation after PCI or CABG for left main disease: the EXCEL Trial. J Am Coll Cardiol 2018; 71(7):739–748. doi:10.1016/j.jacc.2017.12.012.

16. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol 2012; 109(2):219–225. doi:10.1016/j.amjcard.2011.08.033

17. Lowres N, Mulcayh G, Jin K, Gallagher R, Neubeck L, Freedman B. Incidence of postoperative atrial fibrillation recurrence in patients discharged in sinus rhythm after cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2018; 26(3):504–511. doi:10.1093/icvts/ivy348

18. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154(13):1449–1457. pmid:8018000

19. Anderson DC, Halperin JL, Hart RG, et al; The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA 1998; 279(16):1273–1277. pmid:9565007

20. Hart RG, Halperin JL, Pearce LA, et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003; 138(10):831–838. doi:10.7326/0003-4819-138-10-200305200-00011

21. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12):857–867. doi:10.7326/0003-4819-146-12-200706190-00007

22. January CT, Wann LS, Alpert JS, et al. 2019 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74(1):104–132. doi:10.1016/j.jacc.2019.01.011

23. Kollar A, Lick SD, Vasquez KN, Conti VR. Relationship of atrial fibrillation and stroke after coronary artery bypass graft surgery: when is anticoagulation indicated? Ann Thorac Surg 2006; 81(2):513–518. doi:10.1016/j.athoracsur.2005.12.011

### REFERENCES

1. Lee SH, Kang DR, Umh JS, et al. New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft. Am Heart J 2014; 167(4):593–600.e1. doi:10.1016/j.ahj.2013.12.010

2. Melduni RM, Schaff HV, Bailey KR, et al. Implications of new-onset atrial fibrillation after cardiac surgery on long-term prognosis: a community-based study. Am Heart J 2015; 170(4):659–668. doi:10.1016/j.ahj.2015.06.015

3. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56(3):539–549. doi:10.1016/0002-9378(93)90899-n

4. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135(12):1061–1073. doi:10.7326/0002-9378-135-12-200112180-00010

5. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291(14):1720–1729. doi:10.1001/jama.291.14.1720

6. Villareal RP, Harirhan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43(5):742–748. doi:10.1016/j.jacc.2003.11.023

7. Asher CR, Miller DP, Grimm RA, Cosgrove DM 3rd, Chung MK. Analysis of risk factors for development of atrial fibrillation early after cardiac valve surgery. Am J Cardiol 1998; 82(7):892–895. doi:10.1016/s0002-9149(98)00498-6

8. Soucier RJ, Mirza S, Abordo MG, et al. Predictors of conversion of atrial fibrillation after cardiac operation in the absence of class I or III antiarrhythmic medications. Ann Thorac Surg 2001; 72(3):694–698. doi:10.1016/s0002-9149(01)02817-x

9. Lee JK, Klein GJ, Krahn AD, et al. Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results. Card Electrophysiol Rev 2003; 7(2):178–184. doi:10.1023/a:1027428003609

10. Shenasa M, Sanders P, Nattel S (eds). Risk Factors in Atrial Fibrillation: Appraisal of AF Risk Stratification, An Issue of Cardiac Electro-physiology Clinics, 1st ed. E-Book: Elsevier Health Sciences; March 2021.

11. Stamou SC, Dangas G, Hill PC, et al. Atrial fibrillation after beating heart surgery. Am J Cardiol 2000; 86(1):64–67. doi:10.1016/s0002-9149(00)00829-8

12. Lotfi A, Waltrek S, Sethi P, Garb J, Giugliano GR. Postoperative atrial fibrillation is not associated with an increase risk of stroke or the type and number of grafts: a single-center retrospective analysis. Clin Cardiol 2011; 34(12):787–790. doi:10.1002/clc.21001

13. Tarakji KG, Sabik JF 3rd, Bhudia SK, Batizy LH, Blackstone EH. Temporal onset, risk factors, and outcomes associated with stroke after coronary artery bypass grafting. JAMA 2011; 305(4):381–390. doi:10.1001/jama.2011.37
25. Malouf JF, Alam S, Gharzeddine W, Stefadouros MA. The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery. Eur Heart J 1993; 14(11):1451–1457. doi:10.1093/eurheartj/14.11.1451

26. Krawiec F, Maitland A, Duan Q, Faris P, Belletrutti PJ, Kent WDT. Duodenal ulcers are a major cause of gastrointestinal bleeding after cardiac surgery. J Thorac Cardiovasc Surg 2017; 154(1):181–188. doi:10.1016/j.jtcvs.2017.02.012

27. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5):1093–1100. doi:10.1378/chest.10-0134

28. Epstein AE, Alexander JC, Gutierrez DD, Maisel W, Wharton JM; American College of Chest Physicians. Anticoagulation: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005; 128(2 suppl):24S–27S. doi:10.1378/chest.128.2_suppl.24s

29. Mitchell LB; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol 2011; 27(1):91–97. doi:10.1016/j.cjca.2010.11.005

30. Dunning J, Treasure T, Versteegh M, Nashef SA; EACTS Audit and Guidelines Committee. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006; 30(6):852–872. doi:10.1016/ejcts.2006.09.003

31. Anderson E, Johnke K, Leedahl D, Glogoza M, Newman R, Dyke C. Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis. Am J Surg 2015; 210(6):1095–1103. doi:10.1016/j.amjsurg.2015.07.005

32. Sezai A, Osaka S, Yaoto H, Arimoto M, Hata H, Shiono M. Safety of the direct oral anticoagulant edoxaban for atrial fibrillation after cardiac surgery: pilot study. J Atr Fibrillation 2016; 9(3):1456. doi:10.4022/jafib.1456

33. Chapin TW, Leedahl DD, Brown AB, et al. Comparison of anticoagulants for postoperative atrial fibrillation after coronary artery bypass grafting: a pilot study. J Cardiovasc Pharmacol Ther 2020; 25(6):523–530. doi:10.1177/1074284420929483

34. ClinicalTrials.gov. Rivaroxaban vs warfarin for post-cardiac surgery atrial fibrillation (NEW-AF). https://clinicaltrials.gov/ct2/show/NCT03702582. Accessed May 18, 2022.

35. Lowres N, Mulcahy G, Gallagher R, et al. Self-monitoring for atrial fibrillation recurrence in the discharge period post-cardiac surgery using an iPhone electrocardiogram. Eur J Cardiothorac Surg 2016; 50(1):44–51. doi:10.1093/ejcts/ezv486

Address: M. Chadi Alraies, MD, MPH, Wayne State University/Detroit Medical Center, 311 Mack Avenue, Detroit, MI 48201; alraies@hotmail.com